Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_assertion type Assertion NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_head.
- NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_assertion description "[Because solid tumors expressing ECGF-1 could also be lysed by the CTL, ECGF-1 is an interesting target for immunotherapy of both hematologic and solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_provenance.
- NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_assertion evidence source_evidence_literature NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_provenance.
- NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_assertion SIO_000772 16497972 NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_provenance.
- NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_assertion wasDerivedFrom befree-20150227 NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_provenance.
- NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_assertion wasGeneratedBy ECO_0000203 NP364338.RAW1NfDrQBm-Ri3nB83IrSpgjNz8IgMpGG_n3anKVml7U130_provenance.